Moderna reports $1.2bn net loss in Q1 2024 [Yahoo! Finance]
Moderna, Inc. (MRNA)
Last moderna, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
marinabio.com/investor-relations
Company Research
Source: Yahoo! Finance
The company's diluted loss per share stood at $3.07 versus an earnings per share of $0.19 for the same period of the previous year For the three months ending 31 March, total revenue was $167m - a dramatic decrease from $1.9bn in the corresponding period of 2023. The company attributed the decline to the reduced sales of its Covid-19 vaccine. Net product sales plummeted by 91% compared to Q1 2023. This downturn aligns with the expected transition to a seasonal market for Covid-19 vaccines. During Q1 2023, Moderna received revenue from doses deferred from 2022. The cost of sales in Q1 2024 was $96m, which included $8m in third-party royalties, $30m in inventory write-downs and $27m related to unutilised manufacturing capacity and wind-down expenditures. This represents an 88% decrease from Q1 2023. Despite the quarterly loss, Moderna maintains its full-year 2024 guidance. The company reaffirmed anticipated revenue of $4bn from its respiratory franchise. It now expects
Show less
Read more
Impact Snapshot
Event Time:
MRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRNA alerts
High impacting Moderna, Inc. news events
Weekly update
A roundup of the hottest topics
MRNA
News
- Selling US$3.3m Of Moderna Stock Rewarded Insiders [Yahoo! Finance]Yahoo! Finance
- Does AI Really Make Moderna Stock (NASDAQ:MRNA) a Buy? [Yahoo! Finance]Yahoo! Finance
- Moderna wins COVID shot patent case against Pfizer-BioNTech in Europe [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- European Patent Office Sides with Moderna In COVID-19 Vaccine Patent Dispute With Pfizer/BioNTech [Yahoo! Finance]Yahoo! Finance
- Moderna vaccine patent upheld by European Patent Office: report [Seeking Alpha]Seeking Alpha
MRNA
Earnings
- 5/2/24 - Beat
MRNA
Sec Filings
- 5/17/24 - Form 4
- 5/17/24 - Form 4
- 5/15/24 - Form 144
- MRNA's page on the SEC website